CY1121596T1 - Αμιδια βενζοξαζινονης ως αλατοκορτικοειδεις ρυθμιστες υποδοχεα - Google Patents
Αμιδια βενζοξαζινονης ως αλατοκορτικοειδεις ρυθμιστες υποδοχεαInfo
- Publication number
- CY1121596T1 CY1121596T1 CY20191100097T CY191100097T CY1121596T1 CY 1121596 T1 CY1121596 T1 CY 1121596T1 CY 20191100097 T CY20191100097 T CY 20191100097T CY 191100097 T CY191100097 T CY 191100097T CY 1121596 T1 CY1121596 T1 CY 1121596T1
- Authority
- CY
- Cyprus
- Prior art keywords
- benzoxazinone
- amids
- salt
- formula
- endothelial
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 2
- HQQTZCPKNZVLFF-UHFFFAOYSA-N 4h-1,2-benzoxazin-3-one Chemical compound C1=CC=C2ONC(=O)CC2=C1 HQQTZCPKNZVLFF-UHFFFAOYSA-N 0.000 title 1
- 230000001054 cortical effect Effects 0.000 title 1
- 230000003511 endothelial effect Effects 0.000 abstract 2
- -1 benzoxazinone amide Chemical class 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003246 corticosteroid Substances 0.000 abstract 1
- 230000036542 oxidative stress Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000035882 stress Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462018790P | 2014-06-30 | 2014-06-30 | |
| PCT/GB2015/051860 WO2016001631A1 (en) | 2014-06-30 | 2015-06-26 | Benzoxazinone amides as mineralocorticoid receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1121596T1 true CY1121596T1 (el) | 2020-05-29 |
Family
ID=53539739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191100097T CY1121596T1 (el) | 2014-06-30 | 2019-01-24 | Αμιδια βενζοξαζινονης ως αλατοκορτικοειδεις ρυθμιστες υποδοχεα |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US10017502B2 (enExample) |
| EP (1) | EP3160948B1 (enExample) |
| JP (1) | JP6368383B2 (enExample) |
| KR (1) | KR102012222B1 (enExample) |
| CN (1) | CN106536491B (enExample) |
| AR (1) | AR101036A1 (enExample) |
| AU (1) | AU2015282450C1 (enExample) |
| CA (1) | CA2953655C (enExample) |
| CY (1) | CY1121596T1 (enExample) |
| DK (1) | DK3160948T3 (enExample) |
| EA (1) | EA029518B1 (enExample) |
| ES (1) | ES2707726T3 (enExample) |
| HR (1) | HRP20190147T1 (enExample) |
| HU (1) | HUE042370T2 (enExample) |
| LT (1) | LT3160948T (enExample) |
| ME (1) | ME03316B (enExample) |
| MX (1) | MX367404B (enExample) |
| PL (1) | PL3160948T3 (enExample) |
| PT (1) | PT3160948T (enExample) |
| RS (1) | RS58274B1 (enExample) |
| SI (1) | SI3160948T1 (enExample) |
| SM (1) | SMT201900039T1 (enExample) |
| TR (1) | TR201900659T4 (enExample) |
| TW (1) | TWI677498B (enExample) |
| UY (1) | UY36195A (enExample) |
| WO (1) | WO2016001631A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3160948T1 (sl) * | 2014-06-30 | 2020-06-30 | Astrazeneca Ab | Amidi benzoksazinona, kot modulatorji receptorja mineralokortikoida |
| BR112021000139A2 (pt) | 2018-07-19 | 2021-04-06 | Astrazeneca Ab | Métodos de tratamento da hfpef empregando dapagliflozina e composições compreendendo a mesma |
| CN112107568B (zh) * | 2019-06-19 | 2022-03-25 | 北京龙嘉博创医药科技有限公司 | 二芳基酰胺类化合物及其应用 |
| CR20200224A (es) * | 2019-08-30 | 2021-05-26 | Astrazeneca Ab | Composiciones y métodos de tratamiento de la insuficiencia cardiaca con fracción de eyección reducida con dapagliflozina |
| US12409186B2 (en) | 2020-07-27 | 2025-09-09 | Astrazeneca Ab | Methods of treating chronic kidney disease with dapagliflozin |
| CN119192096A (zh) * | 2021-06-15 | 2024-12-27 | 正大天晴药业集团股份有限公司 | 苯并恶嗪酮类衍生物 |
| TW202409023A (zh) | 2022-07-14 | 2024-03-01 | 美商富曼西公司 | 除草苯并𠯤 |
| IL319212A (en) | 2022-09-01 | 2025-04-01 | Astrazeneca Ab | Combination of SGLT2 inhibitors and mineralocorticoid receptor modulators for use in the treatment of heart and kidney disease |
| WO2024125591A1 (zh) * | 2022-12-15 | 2024-06-20 | 正大天晴药业集团股份有限公司 | 苯并恶嗪酮类化合物的结晶及其制备 |
| WO2025111184A1 (en) | 2023-11-21 | 2025-05-30 | Fmc Corporation | Substituted tetrahydroquinoline and tetrahydroquinoxaline herbicides |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6951855B2 (en) * | 2001-04-23 | 2005-10-04 | Astrazeneca Ab | Benzoxazinone derivatives for use in the treatment of angiogenesis |
| AU2003303231A1 (en) * | 2002-12-20 | 2004-07-14 | Warner-Lambert Company Llc | Benzoxazines and derivatives thereof as inhibitors of pi3ks |
| CN101018552A (zh) * | 2004-07-14 | 2007-08-15 | 利亘制药公司 | 细胞内受体调节剂化合物和方法 |
| JP2008508314A (ja) * | 2004-07-28 | 2008-03-21 | アイアールエム・リミテッド・ライアビリティ・カンパニー | ステロイドホルモン核内受容体のモジュレーターとしての化合物および組成物 |
| JP2009523701A (ja) | 2005-12-28 | 2009-06-25 | 武田薬品工業株式会社 | 縮合複素環化合物およびその用途 |
| TWI385161B (zh) | 2006-02-02 | 2013-02-11 | Mitsubishi Tanabe Pharma Corp | 含氮雜雙環化合物 |
| HRP20120078T1 (hr) | 2006-10-31 | 2012-02-29 | Pfizer Products Inc. | Pirazolinski spojevi kao antagonisti mineralokortikoidnih receptora |
| DE102007009494A1 (de) | 2007-02-27 | 2008-08-28 | Bayer Healthcare Ag | Substituierte 4-Aryl-1, 4-dihydro-1,6-naphthyridinamide und ihre Verwendung |
| JP2010522168A (ja) | 2007-03-23 | 2010-07-01 | メルク・シャープ・エンド・ドーム・コーポレイション | 鉱質コルチコイドレセプターモジュレータ |
| PT2133330E (pt) | 2007-04-09 | 2014-03-31 | Daiichi Sankyo Co Ltd | Atropisómero de derivado de pirrole |
| US8258131B2 (en) | 2007-08-01 | 2012-09-04 | Mitsubishi Tanabe Pharma Corporation | Fused bicyclic compound |
| JP5173653B2 (ja) * | 2007-08-01 | 2013-04-03 | 田辺三菱製薬株式会社 | 医薬組成物 |
| TWI431010B (zh) | 2007-12-19 | 2014-03-21 | Lilly Co Eli | 礦皮質素受體拮抗劑及使用方法 |
| CN102124003A (zh) * | 2008-06-18 | 2011-07-13 | 阿斯利康(瑞典)有限公司 | 作为治疗呼吸系统疾病的β2肾上腺素受体拮抗剂的苯并噁嗪酮衍生物 |
| US20100094000A1 (en) | 2008-09-03 | 2010-04-15 | Takeda Pharmaceutical Company Limited | Pyrazole compounds |
| WO2010098286A1 (ja) | 2009-02-25 | 2010-09-02 | 第一三共株式会社 | ミネラルコルチコイド受容体拮抗薬を含有する医薬 |
| WO2010104721A1 (en) | 2009-03-12 | 2010-09-16 | Eli Lilly And Company | Mineralocorticoid receptor antagonist and methods of use |
| EP2417121A1 (en) | 2009-04-10 | 2012-02-15 | Pfizer Inc. | 4, 5-dihydro-1h-pyrazole compounds and their pharmaceutical uses |
| US8979337B2 (en) | 2010-05-11 | 2015-03-17 | Koninklijke Philips N.V. | Lighting module |
| WO2011141848A1 (en) | 2010-05-11 | 2011-11-17 | Pfizer Inc. | Morpholine compounds as mineralocorticoid receptor antagonists |
| TW201216957A (en) | 2010-07-13 | 2012-05-01 | Dainippon Sumitomo Pharma Co | Biarylamide derivative or a pharmaceutically acceptable salt thereof |
| US8722709B2 (en) | 2010-11-10 | 2014-05-13 | Boehringer Ingelheim International Gmbh | Mineralocorticoid receptor antagonists |
| SI3160948T1 (sl) * | 2014-06-30 | 2020-06-30 | Astrazeneca Ab | Amidi benzoksazinona, kot modulatorji receptorja mineralokortikoida |
-
2015
- 2015-06-26 SI SI201530572T patent/SI3160948T1/sl unknown
- 2015-06-26 HU HUE15736015A patent/HUE042370T2/hu unknown
- 2015-06-26 CA CA2953655A patent/CA2953655C/en active Active
- 2015-06-26 JP JP2016575499A patent/JP6368383B2/ja active Active
- 2015-06-26 UY UY0001036195A patent/UY36195A/es not_active Application Discontinuation
- 2015-06-26 DK DK15736015.7T patent/DK3160948T3/en active
- 2015-06-26 EA EA201790046A patent/EA029518B1/ru not_active IP Right Cessation
- 2015-06-26 LT LTEP15736015.7T patent/LT3160948T/lt unknown
- 2015-06-26 PL PL15736015T patent/PL3160948T3/pl unknown
- 2015-06-26 RS RS20190085A patent/RS58274B1/sr unknown
- 2015-06-26 ES ES15736015T patent/ES2707726T3/es active Active
- 2015-06-26 TR TR2019/00659T patent/TR201900659T4/tr unknown
- 2015-06-26 US US15/320,379 patent/US10017502B2/en active Active
- 2015-06-26 AU AU2015282450A patent/AU2015282450C1/en active Active
- 2015-06-26 HR HRP20190147TT patent/HRP20190147T1/hr unknown
- 2015-06-26 WO PCT/GB2015/051860 patent/WO2016001631A1/en not_active Ceased
- 2015-06-26 KR KR1020177002518A patent/KR102012222B1/ko active Active
- 2015-06-26 MX MX2017000183A patent/MX367404B/es active IP Right Grant
- 2015-06-26 ME MEP-2019-19A patent/ME03316B/me unknown
- 2015-06-26 CN CN201580035032.8A patent/CN106536491B/zh active Active
- 2015-06-26 PT PT15736015T patent/PT3160948T/pt unknown
- 2015-06-26 SM SM20190039T patent/SMT201900039T1/it unknown
- 2015-06-26 EP EP15736015.7A patent/EP3160948B1/en active Active
- 2015-06-29 TW TW104120998A patent/TWI677498B/zh active
- 2015-06-29 US US14/753,239 patent/US9394291B2/en active Active
- 2015-06-30 AR ARP150102098A patent/AR101036A1/es active IP Right Grant
-
2019
- 2019-01-24 CY CY20191100097T patent/CY1121596T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1121596T1 (el) | Αμιδια βενζοξαζινονης ως αλατοκορτικοειδεις ρυθμιστες υποδοχεα | |
| CY1122966T1 (el) | 5-βρωμο-2,6-δι-(1η-πυραζολ-1-υλ)πυριμιδιν-4-αμινη για χρηση στη θεραπευτικη αγωγη καρκινου | |
| CY1124548T1 (el) | Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου του δαγκειου ιου | |
| CY1124059T1 (el) | Αζαβενζιμιδαζολια και χρηση αυτων ως ρυθμιστες υποδοχεα ampa | |
| MX377124B (es) | Compuestos heterociclicos y usos de los mismos. | |
| EA201791256A1 (ru) | Производные хиназолина, применяемые для лечения вич | |
| MX379110B (es) | Derivados de azaspiro como antagonistas de trpm8. | |
| MX376833B (es) | Oxiesteroles y metodos de uso de los mismos. | |
| EA201791304A1 (ru) | Производные изохинолина для лечения вич | |
| MX382122B (es) | Oxiesteroles y metodos de uso de los mismos. | |
| CY1124251T1 (el) | Παραγωγα καρβοξαμιδιου | |
| CY1120340T1 (el) | Gpr40 ρυθμιστες πυρρολιδινης για τη θεραπεια ασθενειων οπως διαβητη | |
| CY1121746T1 (el) | Αναστολεις mgat2 τετραζολονο-υποκατεστημενης διυδροπυριδινονης | |
| CY1123576T1 (el) | Συμπυκνωμενα παραγωγα θειοφαινιου χρησιμα ως αναστολεις του napi-iib | |
| MX2017013874A (es) | Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa. | |
| CY1122077T1 (el) | Νεα δακτυλιωμενα φαινοξυακεταμιδια | |
| NI201600091A (es) | UREAS ASIMÉTRICAS p-SUSTITUIDAS Y USOS MÉDICOS DE LAS MISMAS | |
| JOP20190050A1 (ar) | مثبطات دوبامين-b-هيدروكسيلاز تخترق حاجز المخ الدموي | |
| TR201900680T4 (tr) | CXCR3 Reseptör modülatörleri olarak hidroksialkil- piperazin türevleri. | |
| CY1122321T1 (el) | Παραγωγα φθοροϊνδολιου ως θετικοι αλλοστερικοι διαμορφωτες του μουσκαρινικου υποδοχεα μ1 | |
| EP3917926C0 (en) | IMIDAZOQUINOLINE AMINE DERIVATIVES, PHARMACEUTICAL COMPOSITION, THEIR USES | |
| CY1122381T1 (el) | Παραγωγα ιμιδαζοπυριδαζινης ως αναστολεις pi3kbhta | |
| EA201791480A1 (ru) | Новые производные бензимидазола в качестве антигистаминных агентов | |
| CY1123185T1 (el) | Παραγωγα ινδολιου | |
| EA201990723A1 (ru) | Кристаллические формы |